Relationships among Postprandial Plasma Active GLP-1 and GIP Excursions, Skeletal Muscle Mass, and Body Fat Mass in Patients with Type 2 Diabetes Treated with Either Miglitol, Sitagliptin, or Their Combination: A Secondary Analysis of the MASTER Study
Background: We previously conducted a pilot randomized controlled trial “the MASTER study” and demonstrated that alpha-glucosidase inhibitor miglitol and a dipeptidyl peptidase-4 inhibitor sitagliptin modified postprandial plasma excursions of active glucagon-like peptide-1 (aGLP-1) and active gastr...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-04-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/12/9/3104 |
| _version_ | 1797602315366039552 |
|---|---|
| author | Masahiro Sato Hiroki Fujita Hiroki Yokoyama Atsushi Mikada Yohei Horikawa Yuya Takahashi Yuichiro Yamada Hironori Waki Takuma Narita |
| author_facet | Masahiro Sato Hiroki Fujita Hiroki Yokoyama Atsushi Mikada Yohei Horikawa Yuya Takahashi Yuichiro Yamada Hironori Waki Takuma Narita |
| author_sort | Masahiro Sato |
| collection | DOAJ |
| description | Background: We previously conducted a pilot randomized controlled trial “the MASTER study” and demonstrated that alpha-glucosidase inhibitor miglitol and a dipeptidyl peptidase-4 inhibitor sitagliptin modified postprandial plasma excursions of active glucagon-like peptide-1 (aGLP-1) and active gastric inhibitory polypeptide (aGIP), and miglitol treatment decreased body fat mass in patients with type 2 diabetes (T2D). However, the details regarding the relationships among postprandial plasma aGLP-1 and aGIP excursions, skeletal muscle mass, and body fat mass are unclear. Methods: We conducted a secondary analysis of the relationships among skeletal muscle mass index (SMI), total body fat mass index (TBFMI), and the incremental area under the curves (iAUC) of plasma aGLP-1 and aGIP excursions following mixed meal ingestion at baseline and after 24-week add-on treatment with either miglitol alone, sitagliptin alone, or their combination in T2D patients. Results: SMI was not changed after the 24-week treatment with miglitol and/or sitagliptin. TBFMI was reduced and the rates of aGIP-iAUC change were lowered in the two groups treated with miglitol, although their correlations did not reach statistical significance. We observed a positive correlation between the rates of aGIP-iAUC and TBFMI changes and a negative correlation between the rates of TBFMI and SMI changes in T2D patients treated with sitagliptin alone whose rates of aGIP-iAUC change were elevated. Conclusions: Collectively, although T2D patients treated with miglitol and/or sitagliptin did not show altered SMI after 24-week treatment, the current study suggests that there are possible interrelationships among postprandial plasma aGIP excursion modified by sitagliptin, skeletal muscle mass, and body fat mass. |
| first_indexed | 2024-03-11T04:15:22Z |
| format | Article |
| id | doaj.art-95c311812ba047f2b96739d4377eaf16 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-11T04:15:22Z |
| publishDate | 2023-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-95c311812ba047f2b96739d4377eaf162023-11-17T23:10:47ZengMDPI AGJournal of Clinical Medicine2077-03832023-04-01129310410.3390/jcm12093104Relationships among Postprandial Plasma Active GLP-1 and GIP Excursions, Skeletal Muscle Mass, and Body Fat Mass in Patients with Type 2 Diabetes Treated with Either Miglitol, Sitagliptin, or Their Combination: A Secondary Analysis of the MASTER StudyMasahiro Sato0Hiroki Fujita1Hiroki Yokoyama2Atsushi Mikada3Yohei Horikawa4Yuya Takahashi5Yuichiro Yamada6Hironori Waki7Takuma Narita8Department of Metabolism and Endocrinology, Akita University Graduate School of Medicine, Akita 010-8543, JapanDepartment of Metabolism and Endocrinology, Akita University Graduate School of Medicine, Akita 010-8543, JapanJiyugaoka Medical Clinic, Obihiro 080-0016, JapanGastroenterology and Diabetes Unit, Hiraka General Hospital, Yokote 013-8610, JapanGastroenterology and Diabetes Unit, Hiraka General Hospital, Yokote 013-8610, JapanDepartment of Metabolism and Endocrinology, Akita University Graduate School of Medicine, Akita 010-8543, JapanDepartment of Metabolism and Endocrinology, Akita University Graduate School of Medicine, Akita 010-8543, JapanDepartment of Metabolism and Endocrinology, Akita University Graduate School of Medicine, Akita 010-8543, JapanDepartment of Metabolism and Endocrinology, Akita University Graduate School of Medicine, Akita 010-8543, JapanBackground: We previously conducted a pilot randomized controlled trial “the MASTER study” and demonstrated that alpha-glucosidase inhibitor miglitol and a dipeptidyl peptidase-4 inhibitor sitagliptin modified postprandial plasma excursions of active glucagon-like peptide-1 (aGLP-1) and active gastric inhibitory polypeptide (aGIP), and miglitol treatment decreased body fat mass in patients with type 2 diabetes (T2D). However, the details regarding the relationships among postprandial plasma aGLP-1 and aGIP excursions, skeletal muscle mass, and body fat mass are unclear. Methods: We conducted a secondary analysis of the relationships among skeletal muscle mass index (SMI), total body fat mass index (TBFMI), and the incremental area under the curves (iAUC) of plasma aGLP-1 and aGIP excursions following mixed meal ingestion at baseline and after 24-week add-on treatment with either miglitol alone, sitagliptin alone, or their combination in T2D patients. Results: SMI was not changed after the 24-week treatment with miglitol and/or sitagliptin. TBFMI was reduced and the rates of aGIP-iAUC change were lowered in the two groups treated with miglitol, although their correlations did not reach statistical significance. We observed a positive correlation between the rates of aGIP-iAUC and TBFMI changes and a negative correlation between the rates of TBFMI and SMI changes in T2D patients treated with sitagliptin alone whose rates of aGIP-iAUC change were elevated. Conclusions: Collectively, although T2D patients treated with miglitol and/or sitagliptin did not show altered SMI after 24-week treatment, the current study suggests that there are possible interrelationships among postprandial plasma aGIP excursion modified by sitagliptin, skeletal muscle mass, and body fat mass.https://www.mdpi.com/2077-0383/12/9/3104active GLP-1active GIPskeletal muscle massbody fat massmiglitolsitagliptin |
| spellingShingle | Masahiro Sato Hiroki Fujita Hiroki Yokoyama Atsushi Mikada Yohei Horikawa Yuya Takahashi Yuichiro Yamada Hironori Waki Takuma Narita Relationships among Postprandial Plasma Active GLP-1 and GIP Excursions, Skeletal Muscle Mass, and Body Fat Mass in Patients with Type 2 Diabetes Treated with Either Miglitol, Sitagliptin, or Their Combination: A Secondary Analysis of the MASTER Study Journal of Clinical Medicine active GLP-1 active GIP skeletal muscle mass body fat mass miglitol sitagliptin |
| title | Relationships among Postprandial Plasma Active GLP-1 and GIP Excursions, Skeletal Muscle Mass, and Body Fat Mass in Patients with Type 2 Diabetes Treated with Either Miglitol, Sitagliptin, or Their Combination: A Secondary Analysis of the MASTER Study |
| title_full | Relationships among Postprandial Plasma Active GLP-1 and GIP Excursions, Skeletal Muscle Mass, and Body Fat Mass in Patients with Type 2 Diabetes Treated with Either Miglitol, Sitagliptin, or Their Combination: A Secondary Analysis of the MASTER Study |
| title_fullStr | Relationships among Postprandial Plasma Active GLP-1 and GIP Excursions, Skeletal Muscle Mass, and Body Fat Mass in Patients with Type 2 Diabetes Treated with Either Miglitol, Sitagliptin, or Their Combination: A Secondary Analysis of the MASTER Study |
| title_full_unstemmed | Relationships among Postprandial Plasma Active GLP-1 and GIP Excursions, Skeletal Muscle Mass, and Body Fat Mass in Patients with Type 2 Diabetes Treated with Either Miglitol, Sitagliptin, or Their Combination: A Secondary Analysis of the MASTER Study |
| title_short | Relationships among Postprandial Plasma Active GLP-1 and GIP Excursions, Skeletal Muscle Mass, and Body Fat Mass in Patients with Type 2 Diabetes Treated with Either Miglitol, Sitagliptin, or Their Combination: A Secondary Analysis of the MASTER Study |
| title_sort | relationships among postprandial plasma active glp 1 and gip excursions skeletal muscle mass and body fat mass in patients with type 2 diabetes treated with either miglitol sitagliptin or their combination a secondary analysis of the master study |
| topic | active GLP-1 active GIP skeletal muscle mass body fat mass miglitol sitagliptin |
| url | https://www.mdpi.com/2077-0383/12/9/3104 |
| work_keys_str_mv | AT masahirosato relationshipsamongpostprandialplasmaactiveglp1andgipexcursionsskeletalmusclemassandbodyfatmassinpatientswithtype2diabetestreatedwitheithermiglitolsitagliptinortheircombinationasecondaryanalysisofthemasterstudy AT hirokifujita relationshipsamongpostprandialplasmaactiveglp1andgipexcursionsskeletalmusclemassandbodyfatmassinpatientswithtype2diabetestreatedwitheithermiglitolsitagliptinortheircombinationasecondaryanalysisofthemasterstudy AT hirokiyokoyama relationshipsamongpostprandialplasmaactiveglp1andgipexcursionsskeletalmusclemassandbodyfatmassinpatientswithtype2diabetestreatedwitheithermiglitolsitagliptinortheircombinationasecondaryanalysisofthemasterstudy AT atsushimikada relationshipsamongpostprandialplasmaactiveglp1andgipexcursionsskeletalmusclemassandbodyfatmassinpatientswithtype2diabetestreatedwitheithermiglitolsitagliptinortheircombinationasecondaryanalysisofthemasterstudy AT yoheihorikawa relationshipsamongpostprandialplasmaactiveglp1andgipexcursionsskeletalmusclemassandbodyfatmassinpatientswithtype2diabetestreatedwitheithermiglitolsitagliptinortheircombinationasecondaryanalysisofthemasterstudy AT yuyatakahashi relationshipsamongpostprandialplasmaactiveglp1andgipexcursionsskeletalmusclemassandbodyfatmassinpatientswithtype2diabetestreatedwitheithermiglitolsitagliptinortheircombinationasecondaryanalysisofthemasterstudy AT yuichiroyamada relationshipsamongpostprandialplasmaactiveglp1andgipexcursionsskeletalmusclemassandbodyfatmassinpatientswithtype2diabetestreatedwitheithermiglitolsitagliptinortheircombinationasecondaryanalysisofthemasterstudy AT hironoriwaki relationshipsamongpostprandialplasmaactiveglp1andgipexcursionsskeletalmusclemassandbodyfatmassinpatientswithtype2diabetestreatedwitheithermiglitolsitagliptinortheircombinationasecondaryanalysisofthemasterstudy AT takumanarita relationshipsamongpostprandialplasmaactiveglp1andgipexcursionsskeletalmusclemassandbodyfatmassinpatientswithtype2diabetestreatedwitheithermiglitolsitagliptinortheircombinationasecondaryanalysisofthemasterstudy |